Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396550 | 0.73 | MAPT (0.63) | ALDH1A1TDP1CYP3A4TSHRAPP | |
| SCHEMBL29385195 | 0.71 | HSD17B10 (0.48) | ALDH1A1TDP1CYP3A4TSHRAPP | |
| SCHEMBL11211537 | 0.70 | ALDH1A1 (0.42) | ALDH1A1TDP1CYP3A4TSHRMAPT | |
| SCHEMBL8986919 | 0.69 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4TSHRAPP | |
| SCHEMBL28650535 | 0.69 | ALDH1A1 (0.55) | ALDH1A1TDP1CYP3A4TSHRMAPT | |
| SCHEMBL16429878 | 0.68 | ACHE (0.54) | ALDH1A1TDP1CYP3A4TSHRAPP | |
| SCHEMBL3886944 | 0.68 | MAPT (0.89) | ALDH1A1TDP1CYP3A4TSHRAPP | |
| SCHEMBL12491432 | 0.68 | MAPT (0.61) | ALDH1A1APPMAPTMEN1KMT2A | |
| SCHEMBL85646 | 0.67 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4TSHRMAPT | |
| SCHEMBL28198 | 0.67 | CA1 (0.67) | ALDH1A1TDP1APPMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112552312-B | Synthetic method of Ruogeli or salt thereof | 杭州科巢生物科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-111440188-B | Preparation method of Relugol (Relugolix) key intermediate | 江苏海悦康医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8735401-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-1591446-B1 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8058280-B2 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110172249-A1 | METHOD FOR IMPROVING ABSORBABILITY OF PREPARATION, AND PREPARATION HAVING IMPROVED ABSORBABILITY | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2329823-A1 | METHOD FOR IMPROVING ABSORBABILITY OF PREPARATION, AND PREPARATION HAVING IMPROVED ABSORBABILITY | Takeda Pharmaceutical Company Limited (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-20030176360-A1 | Medicinal preparations for treating sex hormone-dependent diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030134863-A1 | Preventives/remedies for alzheimer's disease | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1319409-A1 | SOLID PREPARATIONS | Takeda Chemical Industries, Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| EP-1297850-A1 | MEDICINAL PREPARATIONS FOR TREATING SEX HORMONE-DEPENDENT DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-1291023-A1 | SUSTAINED RELEASE COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-12 | — | — | EP | disclosed |
| CN-1349536-A | Thienopyrimidine compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-05-15 | — | — | CN | disclosed |
| US-6340686-B1 | GONADOTROPIN-RELEASING HORMONE ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1163244-A1 | THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6297379-B1 | GONADOTROPIN RELEASING HORMONE (GNRH, SOMETIMES CALLED LH-RH (LUTEINIZING HORMONE RELEASING HORMONE)) ANTAGONIZING ACTIVITY, TREATING SEX HORMONE-DEPENDENT DISEASES. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| WO-2000056739-A1 | THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134863-A1 | Preventives/remedies for alzheimer's disease | ACHE, GNRHR, PSEN1 | ALDH1A1 2627/4885TDP1 478/4885CYP3A4 4417/4885 |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | ALDH1A1 1567/4885TDP1 1497/4885CYP3A4 826/4885 |
| US-20110172249-A1 | METHOD FOR IMPROVING ABSORBABILITY OF PREPARATION, AND PREPARATION HAVING IMPROVED ABSORBABILITY | SI, SLC10A2, FABP2 | ALDH1A1 1597/4885TDP1 4326/4885CYP3A4 137/4885 |
| US-20030176360-A1 | Medicinal preparations for treating sex hormone-dependent diseases | SHBG, GNRHR, NR5A1 | ALDH1A1 3022/4885TDP1 2877/4885CYP3A4 3383/4885 |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | ALDH1A1 1567/4885TDP1 1497/4885CYP3A4 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.